ENHANCED TUMOR-NECROSIS-FACTOR SUPPRESSION AND CYCLIC ADENOSINE-MONOPHOSPHATE ACCUMULATION BY COMBINATION OF PHOSPHODIESTERASE INHIBITORS AND PROSTANOIDS
B. Sinha et al., ENHANCED TUMOR-NECROSIS-FACTOR SUPPRESSION AND CYCLIC ADENOSINE-MONOPHOSPHATE ACCUMULATION BY COMBINATION OF PHOSPHODIESTERASE INHIBITORS AND PROSTANOIDS, European Journal of Immunology, 25(1), 1995, pp. 147-153
We investigated cooperative effects of phosphodiesterase (PDE) inhibit
ors and prostanoids on cyclic adenosine monophosphate (cAMP) accumulat
ion and tumor necrosis factor (TNF)-alpha synthesis in human periphera
l blood mononuclear cells (PBMC). PDE inhibitors alone induced only a
small increase in cAMP levels in lipopolysaccharide (LPS)-stimulated P
BMC. Cicaprost (a stable analogue of prostacyclin) and pentoxifylline
added simultaneously to LPS-stimulated PBMC (2.0 x 10(6)/ml) induced a
rapid increase of cAMP to a level of 100 nM that peaked within 10 min
and remained at a plateau for up to 4 h. Thus combined prostanoids an
d PDE inhibitors enhanced cAMP accumulation. TNF-alpha suppression in
the presence of pentoxifylline and prostanoids exceeded that of either
drug alone. The potency of different PDE inhibitors (theophylline, pe
ntoxifylline, penthydroxifylline, albifylline, torbafylline, A 80 2715
, amrinone and rolipram) to increase cAMP levels in combination with c
icaprost was evaluated after 1 h of incubation. The dose-dependent inc
rease of cAMP for all PDE inhibitors tested in this combined stimulati
on provided a useful tool for evaluating the potency of PDE inhibitors
on cAMP accumulation. The effective concentration of PDE inhibitors,
which raised cAMP levels to 300% of control, (EC(300)), correlated wit
h the IC50 for TNF-alpha suppression (r = 0.930, p = 0.007, with theop
hylline excluded from the analysis). Interestingly, by contrast, the s
pecific type IV PDE inhibitor rolipram caused only a moderate rise of
accumulated cAMP in the same cells. Our data support cAMP as an essent
ial mediator for TNF-alpha suppression by PDE inhibitors. Furthermore,
an enhanced inhibiting effect on TNF-alpha production may prove thera
peutically advantageous. It may occur in inflammatory and infectious d
iseases in vivo, since high levels of endogenous prostaglandins are li
berated in these conditions.